Glenmark announces discovery and initiation of clinical development of novel anti-cancer drug
The experimental drug, GBR 1372, kills cancer cells by redirecting immune response to destroy cancer cells06-09-2016
06-09-2016
Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel Bispecific Monoclonal Antibody targeting EGFR
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 06, 2016 titled "Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel Bispecific Monoclonal Antibody targeting EGFR".06-09-2016
Glenmark Pharma's growth outlook is improving
With US growth catching pace and domestic growth good, the company's overall outlook remains strong; improvement in free cash-flows can lead to further upgrades30-08-2016
Outcome of AGM
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the minutes of the 38th Annual General Meeting (AGM) of the Company held on August 12, 2016.26-08-2016
Buy Glenmark Pharmaceuticals Ltd., target Rs 895.0 : Independent Analyst
Buy Glenmark Pharmaceuticals Ltd. at a price target of Rs 895.0 and a stop loss at Rs 860.0 from entry point25-08-2016
2 stocks to bet on from Prabhudas Lilladher
Glenmark Pharma and Hexaware Technologies are the two high conviction investment ideas23-08-2016
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on August 12, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report and Proceedings of the Meeting in this regard.13-08-2016
Glenmark Q1 profit rises 24% to Rs.226.8 crore
Glenmark posted a 24% increase in Q1 net profit on the back of strong sales growth across the US, India and Europe markets12-08-2016
Announces Q1 (Standalone & Consolidated) results, Limited Review Report (Standalone & Consolidated), Results Press Release, Management Discussion & Analysis for the Quarter ended June 30, 2016
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended June 30, 2016:The Unaudited Standalone results for the Quarter ended June 30, 2016The Company has posted a net profit of Rs. 5188.05 million for the quarter ended June 30, 2016 as compared to Rs. 3385.73 million for the quarter ended June 30, 2015. Total Income has increased from Rs. 12738.53 million for the quarter ended June 30, 2015 to Rs. 17387.98...12-08-2016
Q1 FY 2016 - 17 Results Earnings Call
Glenmark Pharmaceuticals Ltd has informed BSE regarding "Q1 FY 2016 - 17 Results Earnings Call".08-08-2016